SCHEMBL4153528

SCHEMBL4153528

Cc1cccc(Cl)c1NS(=O)(=O)C1CCC2(C=C1C(=O)O)O[C@H](CO)[C@@H](CO)O2

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.33
LCK P06239 5/20 0.32
MAPK14 Q16539 3/20 0.32
PTGS2 P35354 2/20 0.32
MAPK13 O15264 1/20 0.32
EGFR P00533 1/20 0.32
FYN P06241 1/20 0.32
HCK P08631 1/20 0.32
SRC P12931 1/20 0.32
JAK3 P52333 1/20 0.32
MAPK12 P53778 1/20 0.32
MAPK11 Q15759 1/20 0.32
ACLY P53396 1/20 0.32
IDH1 O75874 1/20 0.32
TLR4 O00206 4/20 0.31
GFER P55789 1/20 0.31
CCR1 P32246 1/20 0.31
TP53 P04637 1/20 0.30
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14136714 1.00 MAPT (0.33) MAPTLCKMAPK14PTGS2MAPK13
SCHEMBL1865124 0.89 TLR4 (0.42) MAPTTLR4TP53MEN1KMT2A
SCHEMBL1869860 0.89 TLR4 (0.42) MAPTTLR4TP53MEN1KMT2A
SCHEMBL14136718 0.88 LCK (0.33) MAPTLCKMAPK14PTGS2MAPK13
SCHEMBL4154931 0.85 PTK2B (0.35) TLR4MEN1KMT2A
SCHEMBL17727700 0.85 PTK2B (0.35) TLR4MEN1KMT2A
SCHEMBL1869861 0.84 MAPT (0.31) MAPTPTGS2
SCHEMBL19970507 0.82 P2RX7 (0.31) CCR1
SCHEMBL4153518 0.82 TLR4 (0.36) TLR4
SCHEMBL4147605 0.81 TLR4 (0.41) MAPTTLR4TP53MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1935879-B1 SUBSTITUTED CYCLOALKENE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2016-05-11 EP disclosed
US-RE43858-E1 Substituted cycloalkene derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-12-11 US disclosed
US-20090233952-A1 SUBSTITUTED CYCLOALKENE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed
EP-1935879-A1 SUBSTITUTED CYCLOALKENE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2008-06-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233952-A1 SUBSTITUTED CYCLOALKENE DERIVATIVE CD40, LITAF, TNF MAPT 4856/4885LCK 409/4885MAPK14 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.